Durch Arbeiten im Rechenzentrum kann die Erreichbarkeit am 20. und 21. April 2024 kurzfristig eingeschränkt sein.
Download
anbr.202000063.pdf 1,23MB
WeightNameValue
1000 Titel
  • Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
1000 Autor/in
  1. Lutz, Halle |
  2. Popowski, Kristen |
  3. Dinh, Phuong-Uyen |
  4. Cheng, Ke |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-12-28
1000 Erschienen in
1000 Quellenangabe
  • 1(3):2000063
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1002/anbr.202000063 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in December 2019 has already infected over 83.7 million people and caused over 1.8 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the coronavirus disease of 2019 (COVID‐19). The different vaccine types investigated for the prevention of COVID‐19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adeno‐associated viruses, virus‐like particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVID‐19 in terms of vaccines and therapeutics.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal coronavirus diseas
lokal nanomedicine
lokal therapeutics
lokal vaccines
lokal exosomes
lokal severe acute respiratory syndrome coronavirus 2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-6364-7627|https://orcid.org/0000-0002-6341-2251|https://orcid.org/0000-0002-8969-6256|https://orcid.org/0000-0001-8053-7059
1000 Label
1000 Förderer
  1. National Institutes of Health |
  2. American Heart Association |
  3. North Carolina Biotechnology Center |
1000 Fördernummer
  1. HL123920; HL137093; HL144002; HL146153; HL147357; HL149940
  2. 18TPA34230092; 19EIA34660286
  3. 2019‐TRG‐6712
1000 Förderprogramm
  1. -
  2. -
  3. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer HL123920; HL137093; HL144002; HL146153; HL147357; HL149940
  2. 1000 joinedFunding-child
    1000 Förderer American Heart Association |
    1000 Förderprogramm -
    1000 Fördernummer 18TPA34230092; 19EIA34660286
  3. 1000 joinedFunding-child
    1000 Förderer North Carolina Biotechnology Center |
    1000 Förderprogramm -
    1000 Fördernummer 2019‐TRG‐6712
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6426861.rdf
1000 Erstellt am 2021-04-15T15:36:39.519+0200
1000 Erstellt von 218
1000 beschreibt frl:6426861
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Wed May 19 11:09:41 CEST 2021
1000 Objekt bearb. Wed May 19 11:08:49 CEST 2021
1000 Vgl. frl:6426861
1000 Oai Id
  1. oai:frl.publisso.de:frl:6426861 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source